Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB – IVA mycosis fungoides/Sézary syndrome-Reference-Cited by-同舟云学术

Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB – IVA mycosis fungoides/Sézary syndrome

Published:2016-06-02 Issue:1 Volume:175 Page:80-88
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Child F.¹,Ortiz‐Romero P.L.²,Alvarez R.³,Bagot M.⁴,Stadler R.⁵,Weichenthal M.⁶,Alves R.⁷,Quaglino P.⁸,Beylot‐Barry M.⁹,Cowan R.¹⁰,Geskin L.J.¹¹,Pérez‐Ferriols A.¹²,Hellemans P.¹³,Elsayed Y.¹⁴,Phelps C.¹⁴,Forslund A.¹⁵,Kamida M.¹⁶,Zinzani P.L.¹⁷

Affiliation:

1. St John's Institute of Dermatology Guy's and St Thomas’ NHS Foundation Trust London U.K.

2. Department of Dermatology 12 de Octubre Hospital Institute i+12 Medical School Complutense University Madrid Spain

3. Portuguese Institute of Oncology Lisbon Portugal

4. Department of Dermatology Saint‐Louis Hospital Paris 7 University Paris France

5. Department of Dermatology Johannes Wesling Medical Center Minden Germany

6. Department of Dermatology University Hospital of Schleswig‐Holstein Kiel Germany

7. Department of Dermatology Hospital de Santo António – Centro Hospitalar do Porto Porto Portugal

8. Department of Medical Sciences Dermatologic Clinic University of Turin Turin Italy

9. Department of Dermatology University Hospital of Bordeaux Bordeaux France

10. Manchester Academic Health Science Centre Christie Hospital Manchester U.K.

11. School of Medicine Department of Dermatology University of Pittsburgh Pittsburgh PA U.S.A.

12. Department of Dermatology University General Hospital Valencia Spain

13. Janssen Research & Development Beerse Belgium

14. Janssen Research & Development Titusville NJ U.S.A.

15. Janssen Research & Development Spring House PA U.S.A.

16. Janssen Pharmaceutical K.K. Tokyo Japan

17. Institute of Hematology ‘Seràgnoli’ University of Bologna Bologna Italy

Funder

Janssen Research and Development

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.14427

Reference30 articles.

1. Primary Cutaneous T-Cell Lymphoma: Review and Current Concepts

2. WHO-EORTC classification for cutaneous lymphomas

3. Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

4. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

5. Review of the Treatment of Mycosis Fungoides and Sézary Syndrome: A Stage-Based Approach

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of the dehydrogenase-reductase DHRS2 and its involvement in histone deacetylase inhibition in urological malignancies;Experimental Cell Research;2024-06

2. What’s New in Cutaneous T-Cell Lymphoma-Associated Pruritus;American Journal of Clinical Dermatology;2023-11-16

3. Harnessing pyrimidine as a building block for histone deacetylase inhibitors;Archiv der Pharmazie;2023-07-18

4. Inhibiteurs d’histones désacétylase et lymphomes T cutanés épidermotropes (mycosis fongoïde et syndrome de Sézary);Annales de Dermatologie et de Vénéréologie - FMC;2023-07

5. Epigenetic Regulations in Autoimmunity and Cancer: from Basic Science to Translational Medicine;European Journal of Immunology;2023-02-23